-
Product Insights
Juvenile Rheumatoid Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Rheumatoid Arthritis - Drugs In Development, 2023’, provides an overview of the Juvenile Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report: Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs. Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA. Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs. Get a detailed assessment of the clinical trials taking place within the...
-
Thematic Analysis
Digital Marketing Trends in Rheumatoid Arthritis
Digital Marketing Trends in Rheumatoid Arthritis Report Overview AbbVie’s Rinvoq.com achieved the highest total traffic across rheumatoid arthritis (RA) patient brand sites in the US, with over four million visitors from February 2022 to January 2023. This was followed by AbbVie’s Humira.com and Amgen’s Enbrel.com. The highest proportion of traffic to branded patient RA websites originated from organic sources, followed by direct. Xeljanz.com was supported by the most paid search engine optimization (SEO) while Amgen spent the most on digital display advertising (DDA)...